Arena Pharmaceuticals Inc

Most Recent

  • uploads///part
    Company & Industry Overviews

    Key Cannabis Sector Updates: Analyst Ratings and Earnings

    Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.

    By Mohit Oberoi, CFA
  • uploads///cannabis _
    Company & Industry Overviews

    Cannabis Stocks Had a Mixed Performance Last Week

    Cannabis ETFs traded on a largely negative note last week.

    By Mohit Oberoi, CFA
  • uploads///hemp leaf _
    Company & Industry Overviews

    Ups and Downs in the Cannabis Space Last Week

    The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.

    By Mohit Oberoi, CFA
  • uploads///stinging nettle _
    Company & Industry Overviews

    Cannabis Updates: New Listings, Price Action, and Ratings

    The cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.

    By Mohit Oberoi, CFA
  • uploads///part
    Earnings Report

    Charlotte’s Web Holdings Reports Record Harvest in 2018

    Charlotte’s Web Holdings (CWBHF) posted a record harvest of 675,000 pounds last year.

    By Mohit Oberoi, CFA
  • uploads///syringe _
    Company & Industry Overviews

    How Much Upside Analysts See In Novavax Stock

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Semaglutide May Prove to Be an Effective Anti-Obesity Therapy

    Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.

    By Margaret Patrick
  • uploads///doctor _
    Company & Industry Overviews

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI Remained Stable as the Markets Rallied on Higher Oil Prices

    On June 8, the biotech and healthcare sectors had a mixed day and remained sluggish. The SPDR S&P Biotech ETF (XBI) gained 0.1% for the day. XBI has fallen by 16.4% on a year-to-date basis.

    By Peter Neil
  • uploads///Pipeline for obesity drugs
    Company & Industry Overviews

    How Much Potential Does Saxenda Hold for Novo?

    Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Arena Rose 14% in XBI’s Small-Cap Space

    Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.